VUF@LNP

VUF@LNP is a lipid-based nanoparticle (LNP) formulation encapsulating VUF11207, a small molecule CXCR7 agonist. Developed by researchers at the National Health Research Institutes (NHRI) in Taiwan and National Cheng Kung University, it is designed for non-invasive intranasal (naso-to-brain) delivery to bypass the blood-brain barrier (BBB). In preclinical models of glioblastoma (GBM), VUF@LNP has been shown to reprogram the immunosuppressive tumor microenvironment by inhibiting CXCL12 release, downregulating PD-L1 on glioblastoma-associated macrophages (GAMs), and increasing CD8+ T-cell infiltration. It is being investigated as a combinatorial therapy with PD-L1 blockade (e.g., anti-PD-L1 antibodies) to improve survival outcomes in glioblastoma.

Other names

VUF11207-encapsulated lipid nanoparticleVUF-11207-encapsulated lipid nanoparticleVUF 11207-encapsulated lipid nanoparticleLNP-encapsulated VUF